Microparticle generation and leucocyte death in Shiga toxin-mediated HUS.
Ge, Shuwang; Hertel, Barbara; Emden, Sang Hi; Beneke, Jan; Menne, Jan; Haller, Hermann; von Vietinghoff, Sibylle.
Nephrol Dial Transplant
; 27(7): 2768-75, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22234918
Shiga Toxin 2a-Induced Endothelial Injury in Hemolytic Uremic Syndrome: A Metabolomic Analysis.
Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.
Multifaceted hemolytic uremic syndrome in pediatrics.
Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.
The Antibiotic Polymyxin B Impairs the Interactions between Shiga Toxins and Human Neutrophils.
Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.
Atypical HUS: time to take stock of current guidelines and outcome measures?
Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.